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Breast cancer is the most commonly diagnosed and
the leading cause of cancer-related deaths among
women worldwide [1]”ISSN”:”00079235”,”PMI
D”:”30207593”,”abstract”:”This article provides
a status report on the global burden of cancer
worldwide using the GLOBOCAN 2018 estimates
of cancer incidence and mortality produced by the
International Agency for Research on Cancer, with
a focus on geographic variability across 20 world
regions. There will be an estimated 18.1 million new
cancer cases (17.0 million excluding nonmelanoma
skin cancer. At present, several treatment
modalities are in clinical practice, including surgery,
hormonal therapy, chemotherapy, radiotherapy, and
immunotherapy or targeted therapy etc. These
therapies could be in the form of a single therapy or
as neo-adjuvant and adjuvant therapies along with
surgery and radiotherapies, based on clinical practice
guidelines and tumour types. Breast tumours could
be luminal-A type (ER+/PR+), luminal-B type
(ER+, /PR+/HER-2+), HER-2+ type or basal-like
triple-negative type (ER-/PR-/HER-2-) [2]. The
majority of breast cancers are luminal-A type, and
are generally treated with hormonal therapies such
as selective estrogen receptor modulators/blockers,
aromatase inhibitors, ovarian suppressants along
with surgery and radiotherapy. On the other hand,
Luminal-B type of breast cancers are treated by
several treatment modalities including hormonal
therapy, chemotherapy, and HER-2 targeted
therapy apart from surgery and radiotherapy.
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HER-2 positive breast cancers are metastatic in
nature and are difficult to treat. Among several
chemotherapeutic agents that are employed to treat
these cancers, only monoclonal antibodies (viz:
trastuzumab and pertuzumab) and tyrosine kinase
inhibitors (Lapatinib) are able to selectively target
the HER-2 receptors and kill these cells. Basal-like
triple-negative breast cancers are highly metastatic
and aggressive in nature and are difficult to contain,
as none of the therapies are able to selectively kill
these types of cancer cells. However, the only option
to treat these types of cancers is to use chemotherapy
apart from surgery and radiotherapy (very toxic),
and hence, the patients’ noncompliance is seen [2].
Immunotherapy is often considered as the better
approach in the treatment of breast cancer because
of its target specificity and fewer toxicities. It
works by stimulating the patients’ own immune
system against cancer cells. The effectiveness of
immunotherapy depends on the ability of individual
patient’s immune systems, and it may not work
equally well as everyone has a different level of
immune system. This is evident from the fact that
the cancer tumour cells may have innate resistance
or have acquired resistance against the cytotoxic
T-cells (CTL) due to the expression of PDL1 at
different levels on the tumour cells. Immunotherapy
can be in the form of artificial antigens/antigenpresenting cells, modified tumour/blood cells,
or antibodies/DNAs to induce immunological
reactions against tumourcells. Immunotherapy
can also be used to enhance the sensitivity of the
chemotherapeutic agents in some cancer types.
Trastuzumab and pertuzumab, the only HER-2
specific monoclonal antibodies, are approved for the
treatment of HER-2 positive breast cancers. Several
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other immunotherapeutic approaches have been
tested in clinical trials for the treatment of breast
cancers.
Vaccines are emerging strategies in cancer
immunotherapy. Breast cancer vaccines are capable
of inducing immunological responses against a
specific tumour or tumour-associated antigens.
The implication of the first cancer vaccine,
Sipuleucel-T, was based on the concept of antigenpresenting cells (APCs) [3]. These cells include
a heterogenous group of white blood cells (i.e., B
lymphocytes, macrophages, and dendritic cells, etc.),
which mediate cellular immune responses upon
recognition by certain lymphocytes (T-lymphocytes
such as CD4 and CD8 cells) after processing and
presenting antigens on their surfaces. Among them,
dendritic cells are more potent in presenting an
antigen and initiating anticancer activities from
naïve T-cells as well as memory T-cells [4]. The
APCs first engulf the invaders or foreign bodies to
take them into the cytoplasm, where they are broken
down into small fragments to process them into
antigens (peptides). These peptide-antigens are then
loaded onto the Class I or Class II MHC molecules
to present the antigens to T-cells. While the CD4Th cells recognize the antigen loaded onto the MAC
Class II molecules on the surface of the APC-cells
through the T-Cell Receptors, the CD8 cells engage
the antigen loaded onto the Class I MHC molecules
on the surface of the APCs or cancer-tumour cells.
Based on the nature of the antigen involved, the
CD4 cells, so activated by the APCs, may induce the
cell mediated immunity (activation of macrophages,
CTLs, NK cells) through the release of cytokines
(such as INFγ, TNFβ, IL2, IL12), or activate the
humoral immunity, through the cytokines such
as IL4, IL5, IL6, IL10, to cause the release of
antibodies. On the other hand, the CD8 cells (CTLs),
upon activation, causes the release of performins
and granizymes, which induce the apoptosis on
the target cells (APC or tumour cells). Hence, all
of the tumour cell vaccines have been modified
genetically to express chemokines, cytokines, or
other costimulatory molecules to stimulate the
immune responses against the tumour cells [5].
2

Passive vaccination refers to the process of
transferring
the
activated
T-lymphocytes,
natural killer cells or ready-made antibodies
as active humoral immunity. The adoptive
T-cell transfer technique is a novel approach in
cellular immunotherapy, in which peritumoral
T-lymphocytes are extracted from the body and
then cultivated and activated for transfusion. These
activated cells can produce a long-lasting response
in more than 25% of cancers [6]the infusion of
large numbers of activated autologous lymphocytes,
can mediate objective tumor regression in a majority
of patients with metastatic melanoma (52 of 93;
56%. In clinical studies, researchers have isolated
the tumour antigen-specific CD8+ T-lymphocytes
from patients’ bone marrow and re-transfused after
activation. About 50% of the metastatic breast
cancer patients showed a significant immunological
response and overall survival as well [7,8]there
has been an increased interest in optimizing this
technology in order to make it a clinically feasible
treatment. One of the main treatment modalities
within cancer immunotherapy has been adoptive T
cell therapy (ACT.
Although natural killer cells possess less potential
than T-lymphocytes, they could still be used for
passive vaccination. As natural killer cells do not
express many surface markers, they can be useful in
helping dendritic cell-based vaccines. However, in
many studies, stem cell-derived natural killer cells
have shown better cytotoxic potential against cancer
cells [9–11]. Moreover, these cells have also shown
synergistic potential with chemotherapeutic agents
in metastatic breast cancer patients [12].
Another interesting perspective, of the adoptive
T-cell transfer technique, in which the T-cells
represent chimeric antigen receptors on their
surfaces, is also studied. In this regard, the T-cells
are extracted from the patients and transfected with
genes that encode particular types of proteins to
express on their cell surface as receptors that can be
recognized by immune cells and then re-administered
into the patients to initiate immunological responses
against cancer cells. For the first time, the FDA has
approved chimeric antigen receptor T-cells as the
first cell-based immunotherapy for leukemia patients
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due to their clinical effectiveness in a randomized
clinical trial [13].
More efforts have been made to develop readymade antibodies such as trastuzumab and
pertuzumab more effectively for the treatment of
HER-2-positive breast cancers. These monoclonal
antibodies specifically bind to HER-2 receptors
and attract immune cells to kill these particular
types of cells. In the clinical setting, trastuzumab,
as a single adjuvant therapy or in combination
with chemotherapy, showed greater effectiveness
and reduced recurrence rate in 50% of the HER-2
positive breast cancer patients [14]. Pertuzumab
has also been approved as a single therapy as well
as in combination with docetaxel and trastuzumab
for the treatment of HER-2 positive breast cancer
[15].
The whole concept of cancer vaccination depends
on the patient’s immune system and cancer types.
Among all the breast cancer types, triple-negative
breast cancer is the most immunogenic and
expresses more MHC Class I molecules on their
cell surfaces, which helps in being recognized by the
T-lymphocytes (CTL); whereas, luminal-A type of
breast cancer cells express very low levels of MHC-I
and are dependent on estrogen for their growth.
These cells are the least immunogenic, which can be
poorly recognized by immune cells and hence, are
less responsive to the immunotherapy. Monoclonal
antibodies that are widely involved in the therapy of
breast cancer, such as trastuzumab and pertuzumab,
target the membrane receptors HER-2; whereas,
atelizumab, which is used against triple-negative
breast cancers, acts as a checkpoint inhibitor. But
its clinical utility is needed to be proven. Moreover,
chemotherapy in combination with immunotherapy,
has been shown to be more effective and hence,
the direct or indirect mechanism for improving
the immune reactivity of chemotherapy is now
becoming interesting and needs to be evaluated.
The vaccine therapy could be a great option for the
immunotherapy, for the prevention as well as the
treatment of breast cancer in the future.
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